Handelsbanken Fonder AB Has $438,000 Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Handelsbanken Fonder AB lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 38.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,800 shares of the medical device company’s stock after buying an additional 4,100 shares during the quarter. Handelsbanken Fonder AB’s holdings in Tandem Diabetes Care were worth $438,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. RiverPark Advisors LLC acquired a new stake in Tandem Diabetes Care in the fourth quarter worth $27,000. Signaturefd LLC grew its holdings in Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after purchasing an additional 1,517 shares during the period. PNC Financial Services Group Inc. grew its holdings in Tandem Diabetes Care by 51.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after purchasing an additional 1,099 shares during the period. Creative Financial Designs Inc. ADV acquired a new stake in Tandem Diabetes Care in the fourth quarter worth $104,000. Finally, Stonebridge Capital Advisors LLC acquired a new stake in Tandem Diabetes Care in the third quarter worth $112,000.

Analyst Ratings Changes

TNDM has been the subject of a number of research reports. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Wells Fargo & Company raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $45.00 in a research note on Monday. Stifel Nicolaus raised their price objective on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, April 23rd. Leerink Partnrs raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. Finally, StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.82.

Tandem Diabetes Care Stock Down 1.3 %

TNDM opened at $36.20 on Thursday. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $40.61. The company’s 50-day moving average is $31.74 and its 200 day moving average is $25.82. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. The firm has a market capitalization of $2.34 billion, a P/E ratio of -10.52 and a beta of 1.12.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The company had revenue of $196.80 million for the quarter, compared to analysts’ expectations of $204.86 million. Research analysts expect that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.